Title: Study of Nitric Oxide Level in Chronic Hepatitis C Egyptian Patients: Relationship to Viremia Level and Antiviral Therapy response
Authors: Mohamed Ahmed Kasem, Akram Abdelmoneim Deghady, Essam Eldin Saeed Bedewy, Ayman Mohamed Shamseya, and Manar Mohamed Rashad
DOI: http://dx.doi.org/10.18535/jmscr/v3i10.52
Abstract
Background and aims: Hepatitis C virus (HCV) infection is a serious global health problem that affects about 180 million people worldwide. Egypt has a very high prevalence of HCV and a high morbidity and mortality from chronic liver disease, cirrhosis, and hepatocellular carcinoma. The goal of antiviral therapy is to cure hepatitis C via a sustained elimination of the virus, which is achieved if the HCV RNA remains negative six months after the end of treatment (sustained virological response, SVR). Nitric oxide (NO) is a short, lived, highly reactive free radical, influences many physiological processes in virtually every organ and tissue. Aim was to study the role of nitric oxide level in chronic hepatitis C patients as a predictor of response to antiviral therapy in relation to the level of viremia.
Patients and methods: 60 subjects were eligible for the study and were classified into two groups: Group I: Included forty HCV patients who were candidates for initiation of antiviral combination therapy, also they were followed 12 weeks after. Group II: Included twenty adult apparently healthy volunteers negative for both HBsAg and HCV Ab and have no clinical or laboratory signs of liver diseases.
Results: there was a significant difference in the post-treatment level of NO between responders and non-responders where the level of NO was higher in responders than in non-responders.
Conclusions: The study concluded that increasing level of serum NO in HCV patients in response to antiviraltherapy can be considered as a predictor of response.
Key-words: antiviral therapy, hepatitis, nitric oxide
References
1. WHO. Hepatitis C Fact sheet 164. (Online at: http://www.who.int/mediacentre/factsheets/fs164/en/) 2014.
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45(4):529-38.
3. Breban R, Doss W, Esmat G, et al. Towards realistic estimates of HCV incidence in Egypt. J Viral Hepat 2013;20:294-296.
4. Mohamoud Y, Mumtaz G, Riome S, Miller D, Abu-Raddad L. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis 2013;13:288.
5. Lange C, Sarrazin C. Diagnostic Tests in Acute and Chronic Hepatitis C. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H (eds). The flying publisher short guide to hepatitis C 2012 edition. German: Flying Publisher &Kamps; 2012. 28-33.
6. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9(6):509-16.
7. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138(2):447-62.
8. Carnovale CE, Ronco MT. Role of nitric oxide in liver regeneration. Ann Hepatol 2012; 11(5):636-47.
9. Zeuzem S, Buti M, Ferenci P. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; (44):97–103.
10. Berg T, Sarrazin C, Herrmann E. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37: 600–9.
11. Poynard T, Marcellin P, Lee SS,Niederau C, Minuk GS, Ideo G, et al. Randomized trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352(9138):1426–32.
12. Navaneethan U, Kemmer N, Neff GW.Predicting the Probable Outcome of Treatment in HCV Patients. TherapAdv Gastroenterol 2009; 2(5):287–302.
13. Everson GT, Hoefs JC, Seeff LB,Bonkovsky HL, Naishadham D, Shiffman ML, et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology 2006; 44(6):1675–84.
14. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an ‘a la carte' combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? thealgovirc project group. Hepatology 2000; 31(1):211–8.
15. Altiparmak E, Saritas Ü, Altintas E, TureyenA, Oguz D, Şahin T. Relationship between histological damage, viral load and serum transaminase levels in patients with chronic hepatitis C. The Turkish Journal of Gastroenterology 2001;12(3):185-8.
16. Hokari A, Zeniya M, Esumi H, Ishikawa T, Kurasima Y, Toda G. Role of nitric oxide (NO) in interferon-alpha therapy for hepatitis C. J Infect 2005;51:47-53.
17. Hokari A, Zeniya M, Esumi H, Kawabe T, Gershwin ME, Toda G. Detection of serum nitrite and nitrate in primary biliary cirrhosis: possible role of nitric oxide in bile duct injury. J Gastroenterol Hepatol 2002; 17(3):308-15.
18. Ibrahim M, Gomaa W, Ibrahim Y, El Hadad H, Shatat M, AleemAA,et al. Nitric oxide levels and sustained virological response to pegylated-interferon alpha2a plus ribavirin in chronic HCV genotype 4 hepatitis: a prospective study. J Gastrointestin Liver Dis 2010; 19(4):387-92.
19. Bogdan C, Rollinghoff M, Diefenbach A. Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity. CurrOpinImmunol 2000; 12(1):64-76.
20. Zaki M, Saudy N, El Diasty A. Study of nitric oxide in patients with chronic hepatitis C genotype 4: Relationship to viremia and response to antiviral therapy. Immunological Investigations 2010; 39(6):598–610.